CoChat

Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells

Open access
Khanna, Anchit, Kauko, Otto, Böckelman, Camilla, Laine, Anni, Schreck, Ilona, Partanen, Johanna I., Szwajda, Agnieszka, Bormann, Stefanie, Bilgen, Turker, Helenius, Merja, Pokharel, Yuba R., Pimanda, John, Russel, Mike R., Haglund, Caj, Cole, Kristina A., Klefström, Juha, Aittokallio, Tero, Weiss, Carsten, Ristimäki, Ari, Visakorpi, Tapio, Westermarck, Jukka · 2013 · Cancer Research

Published version of a preprint

Cited by 46

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Checkpoint kinase Chk1 is constitutively active in many cancer cell types and new generation Chk1 inhibitors show marked antitumor activity as single agents. Here we present a hitherto unrecognized mechanism that contributes to the response of cancer cells to Chk1-targeted therapy. Inhibiting chronic Chk1 activity in cancer cells induced the tumor suppressor activity of protein phosphatase protein phosphatase 2A (PP2A), which by dephosphorylating MYC serine 62, inhibited MYC activity and impaired cancer cell survival. Mechanistic investigations revealed that Chk1 inhibition activated PP2A by decreasing the transcription of cancerous inhibitor of PP2A (CIP2A), a chief inhibitor of PP2A activity. Inhibition of cancer cell clonogenicity by Chk1 inhibition could be rescued in vitro either by exogenous expression of CIP2A or by blocking the CIP2A-regulated PP2A complex. Chk1-mediated CIP2A regulation was extended in tumor models dependent on either Chk1 or CIP2A. The clinical relevance of CIP2A as a Chk1 effector protein was validated in several human cancer types, including neuroblastoma, where CIP2A was identified as an NMYC-independent prognostic factor. Because the Chk1–CIP2A–PP2A pathway is driven by DNA-PK activity, functioning regardless of p53 or ATM/ATR status, our results offer explanative power for understanding how Chk1 inhibitors mediate single-agent anticancer efficacy. Furthermore, they define CIP2A-PP2A status in cancer cells as a pharmacodynamic marker for their response to Chk1-targeted therapy. Cancer Res; 73(22); 6757–69. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-1002

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 27

  1. Sablina, 2008, SV40 small T antigen and PP2A phosphatase in cell transformation, Cancer Metastasis Rev, 27, 137, 10.1007/s10555-008-9116-0 · DOI
  2. Chen, 2010, CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells, Oncogene, 29, 6257, 10.1038/onc.2010.357 · DOI
  3. Guenebeaud, 2010, The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase, Mol Cell, 40, 863, 10.1016/j.molcel.2010.11.021 · DOI · Paper page
  4. Niemelä, 2012, CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes, Oncogene, 31, 4266, 10.1038/onc.2011.599 · DOI · Paper page
  5. Come, 2009, CIP2A is associated with human breast cancer aggressivity, Clin Cancer Res, 15, 5092, 10.1158/1078-0432.CCR-08-3283 · DOI · Paper page
  6. Basu, 2012, Targeting the DNA damage response in oncology: past, present and future perspectives, Curr Opin Oncol, 24, 316, 10.1097/CCO.0b013e32835280c6 · DOI
  7. Smith, 2010, The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer, Adv Cancer Res, 108, 73, 10.1016/B978-0-12-380888-2.00003-0 · DOI · Paper page
  8. Murga, 2011, Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors, Nat Struct Mol Biol, 18, 1331, 10.1038/nsmb.2189 · DOI · Paper page
  9. Tho, 2012, Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis, Oncogene, 31, 1366, 10.1038/onc.2011.326 · DOI
  10. Hoglund, 2011, Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells, Clin Cancer Res, 17, 7067, 10.1158/1078-0432.CCR-11-1198 · DOI
  11. Walton, 2012, CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs, Clin Cancer Res, 18, 5650, 10.1158/1078-0432.CCR-12-1322 · DOI
  12. Fishler, 2010, Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53, Oncogene, 29, 4007, 10.1038/onc.2010.163 · DOI · Paper page
  13. Lopez-Contreras, 2012, An extra alletle of Chk1 limits oncogene-induced replicative stress and promotes transformation, J Exp Med, 209, 455, 10.1084/jem.20112147 · DOI · Paper page
  14. Ma, 2011, Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics, Trends Mol Med, 17, 88, 10.1016/j.molmed.2010.10.009 · DOI · Paper page
  15. Partanen, 2007, Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization, Proc Natl Acad Sci U S A, 104, 14694, 10.1073/pnas.0704677104 · DOI · Paper page
  16. Geerts, 2010, The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification, Int J Cancer, 126, 2012, 10.1002/ijc.25074 · doi:10.1002/ijc.25074
  17. Shimada, 2008, Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression, Cell, 132, 221, 10.1016/j.cell.2007.12.013 · DOI · Paper page
  18. Blasius, 2011, A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1, Genome Biol, 12, R78, 10.1186/gb-2011-12-8-r78 · DOI · Paper page
  19. Khanna, 2011, ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells, PLoS One, 6, e17979, 10.1371/journal.pone.0017979 · DOI · Paper page
  20. Berthon, 1995, Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines, Int J Oncol, 6, 333
  21. Kim, 2008, Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo, PLoS One, 3, e1798, 10.1371/journal.pone.0001798 · DOI · Paper page
  22. Bretones, 2011, SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells, J Biol Chem, 286, 9815, 10.1074/jbc.M110.165977 · DOI
  23. Wilsker, 2008, Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control, Proc Natl Acad Sci U S A, 105, 20752, 10.1073/pnas.0806917106 · DOI · Paper page
  24. Li, 2005, Regulation of CHK2 by DNA-dependent protein kinase, J Biol Chem, 280, 12041, 10.1074/jbc.M412445200 · DOI · Paper page
  25. Lord, 2012, The DNA damage response and cancer therapy, Nature, 481, 287, 10.1038/nature10760 · DOI · Paper page
  26. Curtis, 2012, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, 486, 346, 10.1038/nature10983 · DOI · Paper page
  27. Virshup, 2009, From promiscuity to precision: protein phosphatases get a makeover, Mol Cell, 33, 537, 10.1016/j.molcel.2009.02.015 · DOI · Paper page

Cited by

See all 46

Metadata

Authors
Khanna, A., Kauko, O., Böckelman, C., Laine, A., Schreck, I., Partanen, J. I., Szwajda, A., Bormann, S., Bilgen, T., Helenius, M., Pokharel, Y. R., Pimanda, J., Russel, M. R., Haglund, C., Cole, K. A., Klefström, J., Aittokallio, T., Weiss, C., Ristimäki, A., Visakorpi, T., & Westermarck, J.
Venue
Cancer Research
Published
2013-11-14
Volume
73
Issue
22
Pages
6757-6769
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2052113411
Cited by
46
References
10
FWCI
2.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-1002
The paper
Khanna, A., Kauko, O., Böckelman, C., Laine, A., Schreck, I., Partanen, J. I., Szwajda, A., Bormann, S., Bilgen, T., Helenius, M., Pokharel, Y. R., Pimanda, J., Russel, M. R., Haglund, C., Cole, K. A., Klefström, J., Aittokallio, T., Weiss, C., Ristimäki, A., . . . Westermarck, J. (2013). Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-1002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.